Serological cancer markers
著者
書誌事項
Serological cancer markers
(Contemporary biomedicine)
Humana Press, c1992
大学図書館所蔵 全4件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
The purpose of this book-the fourth volume of a series on Can cer Markers-is intended to provide an updated "status report" on today's use of cancer markers in the diagnosis and monitoring of can cer, with an emphasis on cancer markers detected in the serum. It has been 7 years since the publication of the last volume in this series. The 1980, 1982, and 1985 volumes covered the development of cancer markers, not only in their roles of unraveling the basic biology of can cer, but also as increasingly important players in the management of patients with cancer. During the last 7 years we have seen the applica tion of a number of markers identified by monoclonal antibodies, as well as the beginnings of the use of genetic markers defined by mo lecular probes. Measurements of oncogenes in tissues or cells prom ise many applications for the future, but as yet, these genes have not shown to be useful as serum markers of cancer. The commercial interest in serum markers for cancer, particu larly for the diagnosis and monitoring of tumor patients, is indicated in Chapter 24 by Owen, where the total worldwide market for cancer markers is projected to increase from $148 million in 1988 to $232 million in 1993. The degree of research interest in cancer markers is reflected in the fact that in 1988 a separate category for tumor mark ers was added to Index Medicus.
目次
Cancer Markers of the 1990s: An Introduction. Clinical Cancer Markers: Diagnosis, Prognosis, and Monitoring. Alpha-Fetoprotein in the 1990s. Carcinoembryonic Antigen. Prostate-Specific Antigen. Enzyme Markers. Alkaline Phosphatases as Tumor Markers. Sex-Associated Hormones. Tissue Polypeptide Antigen and Specific TPA. Tumor-Associated Carbohydrate Markers: Chemical and Physical Basis and Cell Biological Implications. Glycoamines: Structural-Functional Characterization of a New Class of Human Tumor Markers. CA 15-3 Assay for the Detection of Episialin: A Serum Marker for Breast Cancer. Clinical Applications of CA 15-3. CA 19-9, GICA (Gastrointestinal Cancer Antigen). Mucin-Like Cancer-Associated Antigen (MCA) as Available Circulating Tumor Marker for Breast Cancer. DU-PAN-2: A Clinically Useful Mucin Marker of Differentiation of Pancreatic and Other Ductal Cells and Their Tumors. CA 50. TAG-72 as a Tumor Marker. CA 125. CA 242. Squamous Cell Carcinoma Antigen. Tumor-Marker Detection by Isotachophoresis in Porous Membranes: Bence-Jones Protein in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma. Multiple Testing with Cancer Markers. New Cancer Products: Predicting Market Success. Comments. Index.
「Nielsen BookData」 より